What Is Tirzepatide?
Tirzepatide is a dual GIP/GLP-1 receptor agonist — the first medication to target both the glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors simultaneously. Developed by Eli Lilly, this dual mechanism produces greater effects on appetite, metabolism, and weight loss than targeting GLP-1 alone.
By activating both receptors, tirzepatide:
- Reduces appetite and food intake through brain signaling
- Slows gastric emptying to increase satiety
- Improves insulin sensitivity and blood sugar regulation
- Enhances fat metabolism
FDA-Approved Forms
| Brand Name | Indication | FDA Approved |
|---|---|---|
| Mounjaro | Type 2 Diabetes | May 2022 |
| Zepbound | Chronic weight management | Nov 2023 |
| Zepbound | Moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity | Dec 2024 |
Both Mounjaro and Zepbound are administered as once-weekly subcutaneous injections using a pre-filled pen.
Clinical Results
SURMOUNT-1 (Weight Management)
Tirzepatide at the highest dose (15 mg) produced an average 22.5% total body weight loss over 72 weeks in adults with obesity — the highest weight loss seen in a pivotal trial for any anti-obesity medication at the time.
SURMOUNT-2 (Type 2 Diabetes + Obesity)
Patients with both type 2 diabetes and obesity lost up to 14.7% of body weight while also achieving significant A1c reductions.
SURMOUNT-5 (Head-to-Head vs. Semaglutide)
In a direct comparison, tirzepatide demonstrated superior weight loss compared to semaglutide 2.4 mg (Wegovy), confirming the advantage of dual receptor targeting.
Dosing Schedule
Tirzepatide uses a gradual dose escalation over several months:
| Period | Dose | Frequency |
|---|---|---|
| Weeks 1-4 | 2.5 mg | Once weekly |
| Weeks 5-8 | 5.0 mg | Once weekly |
| Weeks 9-12 | 7.5 mg | Once weekly |
| Weeks 13-16 | 10.0 mg | Once weekly |
| Weeks 17-20 | 12.5 mg | Once weekly |
| Week 21+ | 15.0 mg (maintenance) | Once weekly |
Your provider may hold you at a lower dose if you're responding well or experiencing side effects. Not every patient needs to reach the maximum dose.
Common Side Effects
Side effects are similar to other GLP-1 medications, though some studies suggest tirzepatide may cause less nausea at lower doses compared to semaglutide:
- Nausea (tends to improve with each dose level)
- Diarrhea
- Constipation
- Decreased appetite
- Abdominal pain
- Injection site reactions
Serious but Rare
- Pancreatitis
- Gallbladder disease
- Hypoglycemia (primarily when combined with insulin or sulfonylureas)
- Thyroid C-cell tumors (observed in animal studies)
Who Should NOT Take Tirzepatide
- Personal or family history of medullary thyroid carcinoma (MTC)
- Personal or family history of Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Pregnancy or planning to become pregnant
- Known hypersensitivity to tirzepatide or any product components
Insurance and Cost
With Commercial Insurance
The Zepbound Savings Card offers eligible commercially insured patients a cost as low as $25 per fill for up to 13 fills. This card expires 12/31/2026. Check with your insurer and the Zepbound savings program for current eligibility.
Self-Pay / LillyDirect
For patients without insurance coverage, Eli Lilly offers the LillyDirect Journey Program:
- $299-$449 per month depending on dose
- Ships directly from Lilly's fulfillment pharmacy
- 45-day refill window
- No insurance required
Retail Pricing
Without savings programs, Zepbound retails at approximately $1,059 per month.
Compounding Status
The FDA has resolved the tirzepatide shortage, which means compounded versions of tirzepatide are no longer legally available from compounding pharmacies. Patients should only obtain tirzepatide through legitimate FDA-approved channels (retail pharmacy or LillyDirect).
How Valitide Helps
Valitide verifies your insurance coverage for Zepbound, assists with Savings Card enrollment for eligible patients, and helps navigate the LillyDirect self-pay pathway when insurance doesn't cover the medication. Our clinical team manages your dosing escalation and monitors your progress throughout treatment.